Paradiem LLC Buys New Holdings in Quest Diagnostics Incorporated $DGX

robot
Abstract generation in progress

Paradiem LLC has acquired a new position in Quest Diagnostics (DGX) during Q4, purchasing 78,670 shares valued at $13.65 million. This investment accounts for 3.3% of Paradiem’s portfolio. Quest Diagnostics recently exceeded Q4 earnings expectations, reported a 7.1% year-over-year revenue increase, and announced a dividend boost along with a $1 billion share buyback program.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments